The potential of statins in xenotransplantation: Commentary

Xenotransplantation

Volumn 14, Issue 2, 2007, Pages 100-103

  Ezzelarab, Mohamed ^a   Cooper, David K C ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; STATIN;

BLOOD CLOTTING; CELL ACTIVATION; CORONARY ARTERY ATHEROSCLEROSIS; ENDOTHELIUM CELL; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNOMODULATION; NONHUMAN; NOTE; PRIORITY JOURNAL; XENOTRANSPLANTATION;

ANIMALS; BLOOD COAGULATION; COMPLEMENT ACTIVATION; ENDOTHELIUM, VASCULAR; GRAFT REJECTION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNE SYSTEM; PRIMATES; SWINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 33947430958     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/j.1399-3089.2007.00389.x     Document Type: Note

References (37)

1. KUWAKI K, TSENG YL, DOR FJMF et al. Heart transplantation in baboons using α1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med 2004; 11: 29-31.
2. TSENG Y-L, KUWAKI K, DOR FJMF et al. α 1,3-galactosyltransferase gene-knockout pig heart transplantation in baboons with survival approaching six months. Transplantation 2005; 80: 1493-1500.
3. HOUSER SL, KUWAKI K, KNOSALLA C et al. Thrombotic microangiopathy and graft arteriopathy in pig hearts following transplantation into baboons. Xenotransplantation 2004; 11: 416-425.
4. SHIMIZU A, YAMADA K, YAMAMOTO S et al. Thrombotic microangiopathic glomerulopathy in human decay accelerating factor-transgenic swine-to-baboon kidney xenografts. J Am Soc Nephrol 2005; 16: 2732-2745.
5. ROBSON SC, COOPER DKC, D'APICE AJF. Disordered regulation of coagulation and platelet activation in xenotransplantation. Xenotransplantation 2000; 7: 166-176.
6. DORLING A, LECHLER RI. Disordered thromboregulation after xenografting. Curr Opin Organ Transplant 2001; 6: 36-41.
7. KOBASHIGAWA JA, KATZNELSON S, LAKS H et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-627.
8. KATZNELSON S, KOBASHIGAWA JA. Dual roles of HMGCoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression. Kidney Int Suppl 1995; 52: S112-S115.
9. KATZNELSON S, WILKINSON AH, KOBASHIGAWA JA et al. The effect of pravastatin on acute rejection after kidney transplantation - a pilot study. Transplantation 1996; 61: 1469-1474.
10. KOBASHIGAWA JA. Statins as immunosuppressive agents. Liver Transpl 2001; 7: 559-561.
11. KOBASHIGAWA JA. Statins in solid organ transplantation: is there an immunosuppressive effect? Am J Transplant 2004; 4: 1013-1018.
12. KOBASHIGAWA JA. Statins and cardiac allograft vasculopathy after heart transplantation. Semin Vasc Med 2004; 4: 401-406.
13. KOBASHIGAWA JA, MORIGUCHI JD, LAKS H et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 2005; 24: 1736-1740.
14. VEILLARD NR, MACH F. Statins: the new aspirin? Cell Mol Life Sci 2002; 59: 1771-1786.
15. ETO M, KOZAI T, COSENTINO F, JOCH H, LÜSCHER TF. Statin prevents tissue factor expression in human endothelial cells role of Rho/Rho-kinase and Akt pathways. Circulation 2002; 105: 1756-1759.
16. AIKAWA M, RABKIN E, SUGIYAMA S et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001; 103: 276-283.
17. UNDAS A, BRUMMEL KE, MUSIAL J, MANN KG, SZCZEKLIK A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001; 103: 2248-2253.
18. LACOSTE L, LAM JYT, HUNG J et al. Hyperlipidemia and coronary disease correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172-3177.
19. SHI J, WANG J, ZHENG H et al. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric-oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis 2003; 14: 575-585.
20. MASAMURA K, OIDA K, KANEHARA H et al. Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol 2003; 23: 512-517.
21. KANEIDER NC, EGGER P, DUNZENDORFER S et al. Reversal of thrombin-induced deactivation of CD39/ ATPDase in endothelial cells by HMG-CoA reductase inhibition effects on Rho-GTPase and adenosine nucleotide metabolism. Arterioscler Thromb Vasc Biol 2002; 22: 894-900.
22. HUHLE G, ABLETSHAUSER C, MAYER N et al. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res 1999; 95: 229-234.
23. PUCCETTI L, PASQUI AL, PASTORELLI M et al. Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest 2002; 32: 901-908.
24. O'DRISCOLL G, GREEN D, TAYLOR RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-1131.
25. TREASURE CB, KLEIN JL, WEINTRAUB WS et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 32: 481-487.
26. LEFER AM, CAMPBELL B, SHIN YK et al. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999; 100: 178-184.
27. IKEDA Y, YOUNG LH, LEFER AM. Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats. J Cardiovasc Pharmacol 2003; 41: 649-656.
28. KUREISHI Y, LUO Z, SHIOJIMA I et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 7: 1004-1010.
29. WOLFRUM S, DENDORFER A, SCHUTT M et al. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol 2004; 44: 348-355.
30. MEZZETTI RM, MARULLI A, CIABATTONI C et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J Investig Med 2000; 48: 183-189.
31. FISCHETTI FA, TEDESCO F. Cross-talk between the complement system and endothelial cells in physiologic conditions and in vascular diseases. Autoimmunity 2006; 39: 417-428.
32. KINDERLERER AR, STEINBERG R, JOHNS M et al. Statin-induced expression of CD59 on vascular endothelium in hypoxia: a potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis. Arthritis Res Ther 2006; 8: R130 (Epub).
33. MASON JC, AHMED Z, MANKO R et al. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. Circ Res 2002; 91: 696-703.
34. KWAK B, MULHAUPT F, MYIT S, MACH F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399-1402.
35. WEITZ-SCHMIDT G, WELZENBACH K, BRINKMANN V et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-692.
36. YILMAZ A, REISS C, TANTAWI O et al. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 2004; 172: 85-93.
37. GEISSLER I, COLLINS L, SCHOFIELD R, FABRE JW. In vivo suppression of major histocompatibility complex class II expression on porcine vascular endothelial cells by an HMG-CoA reductase inhibitor. Transplantation 2006; 81: 922-926.